Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Rinke, Anja; Müller, Hans‐Helge; Schade‐Brittinger, Carmen; Klose, Klaus‐Jochen; Barth, Peter; Wied, M.; Mayer, Christina; Aminossadati, Behnaz; Pape, Ulrich‐Frank; Bläker, Michael; Harder, Jan; Arnold, Christian; M. Gress, Thomas; Arnold, Rudolf

doi:10.1200/jco.2009.22.8510

Public

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Published in Journal of Clinical Oncology • Aug 24, 2009

Authors:

Anja Rinke

Hans‐Helge Müller

Carmen Schade‐Brittinger

Abstract

PURPOSE: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metastatic NETs is a matter of debate. We performed a placebo-controlled, double-blin...

Subject

Medicine

Octreotide

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!